Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Mo Qatanani Sells 68,510 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the sale, the insider now directly owns 111,084 shares of the company’s stock, valued at approximately $4,154,541.60. The trade was a 38.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Scholar Rock Stock Performance

Shares of SRRK traded up $1.14 during trading hours on Thursday, hitting $39.15. The stock had a trading volume of 670,911 shares, compared to its average volume of 911,591. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The firm has a market capitalization of $3.67 billion, a PE ratio of -16.66 and a beta of 0.50. The stock has a fifty day moving average price of $41.94 and a 200 day moving average price of $28.09.

Institutional Trading of Scholar Rock

Large investors have recently modified their holdings of the company. Wellington Management Group LLP grew its holdings in shares of Scholar Rock by 16.2% in the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company’s stock worth $1,600,000 after acquiring an additional 27,801 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Scholar Rock by 9.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock valued at $4,027,000 after purchasing an additional 42,139 shares during the period. Barclays PLC grew its holdings in Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock valued at $1,324,000 after purchasing an additional 84,118 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Scholar Rock by 7.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company’s stock valued at $759,000 after purchasing an additional 6,269 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Scholar Rock by 8.5% during the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock valued at $12,361,000 after purchasing an additional 120,489 shares during the period. Institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a report on Wednesday, January 29th. HC Wainwright lifted their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Truist Financial lifted their target price on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $40.43.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.